The clinical hold lift removes the primary overhang on the stock. The next catalyst is the start of patient screening in Q1 2027 and eventual Phase 2a data. Monitor for site initiation announcements and any protocol amendments.
Price Chart
Executive Summary
Filana Therapeutics announced that the FDA has lifted the full clinical hold on its IND for simufilam, enabling the company to initiate a planned Phase 2a proof-of-concept study in TSC-related epilepsy. Patient screening is expected to begin by Q1 2027, removing a key regulatory overhang and allowing the program to advance.
Key Facts
- FDA lifted full clinical hold on IND for simufilam in TSC-related epilepsy on September 22, 2026.
- Phase 2a trial is a 16-week, randomized, double-blind study at 13 U.S. sites targeting 40 patients aged 12-55.
- Patient screening expected to begin by Q1 2027; a 48-week extension study is planned for completers.
- Preclinical data from two mouse models showed simufilam reduced seizure frequency and attenuated seizure progression in a dose-dependent manner.
- Filana holds an exclusive worldwide license from Yale University for simufilam in TSC-related epilepsy.
Financial Impact
No financial figures provided; the clinical hold lift removes a binary regulatory risk and enables the start of a Phase 2a trial, which is a significant pipeline catalyst for a pre-revenue biotech.
Risk Factors
- Phase 2a may fail to show efficacy or safety issues may arise, given the small 40-patient sample size.
- Enrollment delays or protocol changes could push timelines beyond Q1 2027 guidance.
- The company has no approved products and relies on successful clinical development and financing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006161 |
| Exhibit: exh_991.htm | 0001171843-26-006161 |
| Document: 0001171843-26-006161-index-headers.html | 0001171843-26-006161 |
| Document: 0001171843-26-006161-index.html | 0001171843-26-006161 |
| Document: 0001171843-26-006161.txt | 0001171843-26-006161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6351 (−7.76%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6351 (−38.34%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6351 (+14.12%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6351 (−26.97%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6351 (−47.51%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6351 (+53.30%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6351 (−53.30%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6351 (+67.43%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6351 (−73.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers